drugset / Trial / NCT01297569

Ranibizumab "Treat and Extend" in Diabetic Macular Edma

NCT01297569

Phase 4 Completed 7 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.

Timeline

Start
2011-01
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody